Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Gynecologic 2Genitourinary 2Thoracic 1Other hematologic neoplasm 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1

Interventions

lutetium Lu 177 dotatate 14Nivolumab 11Magnetic Resonance Spectroscopy 11pembrolizumab 10Specimen Handling 10cabozantinib 8Ipilimumab 8trametinib 6lenvatinib 6Temozolomide 6dabrafenib 4atezolizumab 4Lutetium-177 4Immunoglobulin G 4Everolimus 4Disulfides 4CTLA-4 Antigen 4selpercatinib 3Octreotide 3Cisplatin 3Carboplatin 3Capecitabine 3Bevacizumab 3fludarabine 2entrectinib 2copper dotatate CU-64 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × talazoparib × Endocrine × Clear all
NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡